{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:18:36Z","timestamp":1777555116007,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ketamine, dimethyltryptamine, DMT, phencyclidine, PCP, dextromethorphan, psilocybin, and ayahuasca), and dermatosis terms (dermatitis, contact dermatitis, drug eruption, skin reaction, and urticaria). Studies were included if there was an association with a psychedelic or hallucinogenic and any cutaneous reaction; studies without both components were excluded. Twenty-two studies met inclusion criteria, describing reactions to cannabis (10 studies), MDMA (5 studies), ketamine (4 studies), and psilocybin (3 studies). Forty total patients were included. Among cannabis-related reactions, the most common reaction was type I hypersensitivity by topical exposure (n\u2009=\u200921). Three patients reported type IV hypersensitivity reactions to contact with cannabis or cannabis-derived oils, all of whom experienced vesicular contact dermatitis. Two additional patients presented with an erythema-multiforme-like reaction and acute generalized exanthematous pustulosis after systemic administration, respectively. MDMA was associated with acneiform eruptions (2 cases), an urticarial eruption, a guttate psoriasis-like reaction, a fixed drug eruption, and Stevens\u2013Johnson syndrome (1 case). Four patients reported type I hypersensitivity reactions to ketamine. Four patients reported vesicular eruptions, cyanosis, or widespread jaundice to psilocybin. Of the cases, 8 patients had cutaneous reactions that resolved with drug cessation, 10 resolved with cessation plus treatment, and resolution in 7 cases was not reported. Zero studies were found describing other psychedelic or hallucinogenic compounds. Further research is required to characterize reactions and treatments linked to the variety of extant psychedelics and hallucinogens.\n                  <\/jats:p>","DOI":"10.1089\/derm.2023.0292","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:45:02Z","timestamp":1713437102000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Trips through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3763-6561","authenticated-orcid":false,"given":"Syed Minhaj","family":"Rahman","sequence":"first","affiliation":[{"name":"From the,  College of Medicine, University of Rochester School of Medicine &amp; Dentistry, Rochester, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-3841","authenticated-orcid":false,"given":"Yousef","family":"Salem","sequence":"additional","affiliation":[{"name":"Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir","family":"Hussain","sequence":"additional","affiliation":[{"name":"Galaria Plastic Surgery &amp; Dermatology, LLC, Chantilly, Virginia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718001356"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05817-8"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884703"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0013"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1995"},{"key":"e_1_3_1_7_2","unstructured":"Goodman B. FDA may review MDMA for the treatment of PTSD. 12\/12\/2023. Available at https:\/\/www.cnn.com\/2023\/12\/12\/health\/fda-mdma-ptsd\/index.html#:~:text=The%20FDA%20granted%20MDMA%2Dassisted breakthrough%20therapy%20designation%20in%202017.&text=The%20US%20Food%20and%20Drug for%20post%2Dtraumatic%20stress%20disorder. Accessed January12 2023."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.1957183"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2003.11.002"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2016.02.004"},{"key":"e_1_3_1_11_2","unstructured":"Cohen B Ruth LJ Preuss CV. Opioid analgesics. In: StatPearls. StatPearls Publishing; 2023. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459161\/. Accessed January14 2024."},{"issue":"2","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0105-1873.2006.0560h.x","article-title":"Contact urticaria to Cannabis sativa","volume":"54","author":"Majmudar V","year":"2006","unstructured":"Majmudar V, , Azam NAM, , Finch T. Contact urticaria to Cannabis sativa. Contact Dermatitis. 2006; 54(2):127\u2013127.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-0536.2007.01169.x","article-title":"Work-related contact urticaria to Cannabis sativa","volume":"58","author":"Williams C","year":"2007","unstructured":"Williams C, , Thompstone J, , Wilkinson M. Work-related contact urticaria to Cannabis sativa. Contact Dermatitis. 2007; 58(1):62\u201363.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/0019-5154.55639","article-title":"Contact urticaria: present scenario","volume":"54","author":"Maibach H","year":"2009","unstructured":"Maibach H, , Bhatia R, , Alikhan A. Contact urticaria: present scenario. Indian J Dermatol. 2009; 54(3):264.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.anai.2012.01.008","article-title":"Hypersensitivity reactions to marijuana","volume":"108","author":"Tessmer A","year":"2012","unstructured":"Tessmer A, , Berlin N, , Sussman G, et al. Hypersensitivity reactions to marijuana. Ann Allergy Asthma Immunol. 2012; 108(4):282\u2013284.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000115887","article-title":"Sensitization and allergy to Cannabis sativa leaves in a population of tomato (Lycopersicon esculentum)-sensitized patients","volume":"146","author":"De Larramendi CH","year":"2008","unstructured":"De Larramendi CH, , Carn\u00e9s J, , Garc\u00eda-Abujeta JL, et al. Sensitization and allergy to Cannabis sativa leaves in a population of tomato (Lycopersicon esculentum)-sensitized patients. Int Arch Allergy Immunol. 2008; 146(3):195\u2013202.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.aller.2010.09.008","article-title":"Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users","volume":"39","author":"Armentia A","year":"2011","unstructured":"Armentia A, , Castrodeza J, , Ruiz-Mu\u00f1oz P, et al. Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users. Allergol Immunopathol. 2011; 39(5):271\u2013279.","journal-title":"Allergol Immunopathol"},{"issue":"1","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-021-00552-3","article-title":"Selective cannabis strain allergy in a patient presenting with a local allergic reaction","volume":"17","author":"Stepaniuk P","year":"2021","unstructured":"Stepaniuk P, , Kanani A. Selective cannabis strain allergy in a patient presenting with a local allergic reaction. Allergy Asthma Clin Immunol. 2021; 17(1):49.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/occmed\/kqac020","article-title":"Occupational contact urticaria to cannabis sativa","volume":"72","author":"Yeo L","year":"2022","unstructured":"Yeo L, , Debusscher C, , White JML. Occupational contact urticaria to cannabis sativa. Occup Med. 2022; 72(4):273\u2013275.","journal-title":"Occup Med"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000378"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000869"},{"issue":"3","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cod.14142","article-title":"Allergic contact dermatitis from Cannabis sativa (hemp) seed oil","volume":"87","author":"Clark E","year":"2022","unstructured":"Clark E, , Nilsson U, , Samaran Q, et al. Allergic contact dermatitis from Cannabis sativa (hemp) seed oil. Contact Dermatitis. 2022; 87(3):292\u2013293.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/j.1365-4632.2011.05318.x","article-title":"Cannabis-induced erythema multiforme-like recurrent drug eruption: correspondence","volume":"53","author":"Ozyurt S","year":"2014","unstructured":"Ozyurt S, , Muderrisoglu F, , Ermete M, et al. Cannabis-induced erythema multiforme-like recurrent drug eruption: correspondence. Int J Dermatol. 2014; 53(1):e22\u2013e23.","journal-title":"Int J Dermatol"},{"issue":"3","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/archderm.143.3.430","article-title":"Acute generalized exanthematous pustulosis caused by illicit street drugs?","volume":"143","author":"Lu LK","year":"2007","unstructured":"Lu LK, , High WA. Acute generalized exanthematous pustulosis caused by illicit street drugs?. Arch Dermatol. 2007; 143(3):423.","journal-title":"Arch Dermatol"},{"key":"e_1_3_1_25_2","unstructured":"Orhurhu VJ Vashisht R Claus LE et al. Ketamine toxicity. In: StatPearls. StatPearls Publishing; 2023. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541087\/. Accessed September17 2023."},{"issue":"7","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"E94","DOI":"10.1111\/papr.12466","article-title":"Immunoglobulin E-mediated hypersensitivity reaction to ketamine","volume":"16","author":"Ozcan J","year":"2016","unstructured":"Ozcan J, , Nicholls K, , Jones K. Immunoglobulin E-mediated hypersensitivity reaction to ketamine. Pain Pract. 2016; 16(7):E94\u2013E98.","journal-title":"Pain Pract"},{"issue":"4","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jemermed.2016.09.020","article-title":"Allergic reaction to ketamine as monotherapy for procedural sedation","volume":"52","author":"Nguyen TT","year":"2017","unstructured":"Nguyen TT, , Baker B, , Ferguson JD. Allergic reaction to ketamine as monotherapy for procedural sedation. J Emerg Med. 2017; 52(4):562\u2013564.","journal-title":"J Emerg Med"},{"issue":"2","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.17796\/jcpd.31.2.6q619k3664634250","article-title":"An allergic reaction following intramuscular administration of ketamine and midazolam","volume":"31","author":"Boynes S","year":"2007","unstructured":"Boynes S, , Lemak A, , Skradski D, et al. An allergic reaction following intramuscular administration of ketamine and midazolam. J Clin Pediatr Dent. 2007; 31(2):77\u201379.","journal-title":"J Clin Pediatr Dent"},{"issue":"5","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/bja\/47.5.624","article-title":"Reaction to ketamine: anaphylactoid or anaphylactic?","volume":"47","author":"Mathieu A","year":"1975","unstructured":"Mathieu A, , Goudsouzian N, , Snider MT. Reaction to ketamine: anaphylactoid or anaphylactic?. Br J Anaesth. 1975; 47(5):624\u2013627.","journal-title":"Br J Anaesth"},{"issue":"7","key":"e_1_3_1_30_2","first-page":"917","article-title":"The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs","volume":"165","author":"Kalant H","year":"2001","unstructured":"Kalant H. The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs. CMAJ. 2001; 165(7):917\u2013928.","journal-title":"CMAJ"},{"issue":"2","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000017992","article-title":"Ecstasy pimples\u2014a new facial dermatosis","volume":"197","author":"Wollina U","year":"1998","unstructured":"Wollina U, , Kammler HJ, , Hesselbarth N, et al. Ecstasy pimples\u2014a new facial dermatosis. Dermatology. 1998; 197(2):171\u2013173.","journal-title":"Dermatology"},{"issue":"6","key":"e_1_3_1_32_2","first-page":"853","article-title":"Facial eruption related to snorting ecstasy","volume":"20","author":"G\u00f3mez-Fern\u00e1ndez C","year":"2010","unstructured":"G\u00f3mez-Fern\u00e1ndez C, , Feito Rodr\u00edguez M, , Casado Verrier B, et al. Facial eruption related to snorting ecstasy. Eur J Dermatol. 2010; 20(6):853\u2013854.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ajd.13265","article-title":"Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis associated with ecstasy exposure","volume":"61","author":"Wetzel M","year":"2020","unstructured":"Wetzel M, , Surkhabi W, , Jung JY. Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis associated with ecstasy exposure. Aust J Dermatol. 2020; 61(3):276\u2013277.","journal-title":"Aust J Dermatol"},{"issue":"3","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-0960.2004.00080.x","article-title":"Guttate psoriasis following ecstasy ingestion","volume":"45","author":"Tan B","year":"2004","unstructured":"Tan B, , Foley P. Guttate psoriasis following ecstasy ingestion. Australas J Dermatol. 2004; 45(3):167\u2013169.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cod.14132","article-title":"Ecstasy-induced fixed drug eruption","volume":"87","author":"Barbier O","year":"2022","unstructured":"Barbier O, , Galadari A, , Milpied B, et al. Ecstasy-induced fixed drug eruption. Contact Dermatitis. 2022; 87(3):280\u2013281.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231190858"},{"issue":"3","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaclp.2020.12.012","article-title":"A \u201ctrip\u201d to the intensive care unit: an intravenous injection of psilocybin","volume":"62","author":"Giancola NB","year":"2021","unstructured":"Giancola NB, , Korson CJ, , Caplan JP, et al. A \u201ctrip\u201d to the intensive care unit: an intravenous injection of psilocybin. J Acad Consult Liaison Psychiatry. 2021; 62(3):370\u2013371.","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(85)80643-0"},{"issue":"3","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5694\/j.1326-5377.1984.tb103978.x","article-title":"Intravenous injection of mushrooms","volume":"140","author":"Sivyer G","year":"1984","unstructured":"Sivyer G, , Dorrington L. Intravenous injection of mushrooms. Med J Aust. 1984; 140(3):182\u2013182.","journal-title":"Med J Aust"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1224551"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2023.0292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:08:47Z","timestamp":1777399727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2023.0292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["10.1089\/derm.2023.0292"],"URL":"https:\/\/doi.org\/10.1089\/derm.2023.0292","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}